Zhejiang Dayang Biotech Group Co (003017) — Capital Reinvestment Ratio
Zhejiang Dayang Biotech Group Co (003017) has a Capital Reinvestment Ratio of 27.69x as of September 2025, meaning it reinvests 28% of its operating cash flow (CN¥638.25K) in capital expenditures (CN¥17.67 Million). Check Zhejiang Dayang Biotech Group Co tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Zhejiang Dayang Biotech Group Co Capital Reinvestment Ratio (2013–2025)
This chart tracks Zhejiang Dayang Biotech Group Co's Capital Reinvestment Ratio across 12 annual periods. For the full cash flow conversion analysis, see 003017 cash generation efficiency.
Annual Capital Reinvestment Ratio for Zhejiang Dayang Biotech Group Co (2013–2025)
Year-by-year Capital Reinvestment Ratio for Zhejiang Dayang Biotech Group Co from 2013 to 2025. See Zhejiang Dayang Biotech Group Co free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.48x | CN¥160.11 Million | CN¥76.38 Million | ▼ -50.2% |
| 2024 | 0.96x | CN¥66.19 Million | CN¥63.45 Million | ▲ +68.7% |
| 2023 | 0.57x | CN¥182.42 Million | CN¥103.63 Million | ▼ -50.1% |
| 2022 | 1.14x | CN¥91.89 Million | CN¥104.65 Million | ▲ +2.6% |
| 2020 | 1.11x | CN¥112.49 Million | CN¥124.82 Million | ▲ +102.9% |
| 2019 | 0.55x | CN¥113.09 Million | CN¥61.84 Million | ▼ -51.9% |
| 2018 | 1.14x | CN¥38.77 Million | CN¥44.05 Million | ▲ +106.7% |
| 2017 | 0.55x | CN¥48.64 Million | CN¥26.73 Million | ▼ -8.7% |
| 2016 | 0.60x | CN¥84.63 Million | CN¥50.95 Million | ▼ -32.4% |
| 2015 | 0.89x | CN¥48.95 Million | CN¥43.57 Million | ▲ +31.6% |
| 2014 | 0.68x | CN¥57.73 Million | CN¥39.04 Million | ▲ +50.8% |
| 2013 | 0.45x | CN¥91.64 Million | CN¥41.09 Million | — |